Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORAb-003 (Farletuzumab) in Platinum-Sensitive Ovarian Cancer First Relapse
NCT00318370Phase 2Completed
- Sponsor
- Morphotek
- Start
- May 2006
- Primary completion
- Feb 2010
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of farletuzumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Morphotek. Started May 2006; status: completed.
02
Drugs
farletuzumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00318370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00318370.